Merck's Quadrivalent HPV Vaccine Receives New Indication Approval in China for Females Aged 9-19
MSD
Pharmaceutical R&D and Manufacturer
On November 23, MSD announced that its quadrivalent human papillomavirus (HPV) vaccine (recombinant Saccharomyces cerevisiae) (hereinafter referred to as the “quadrivalent HPV vaccine”) had received marketing approval from the National Medical Products Administration for use in females aged 9–19 years. This means that the eligible population for vaccination with this vaccine has been expanded to include females aged 9–45 years, while still adhering to a three-dose immunization schedule. The quadrivalent HPV vaccine is indicated for the prevention of cervical cancer, cervical intraepithelial neoplasia grades 2 and 3 (CIN2/3), and adenocarcinoma in situ (AIS) caused by high-risk HPV types 16 and 18, as well as cervical intraepithelial neoplasia grade 1 (CIN1).
References:
[1] MSD’s Quadrivalent Human Papillomavirus Vaccine Approved for New Indications in China. Retrieved 2020-11-23, from https://mp.weixin.qq.com/s/T2NvDVhHBI_9ZyjZBCahCw
Source: Jike Pharma News
*Disclaimer: This article was written by an author contributing to Sina Medical News. The views expressed are solely those of the author and do not represent the position of Sina Medical News.▽Follow [WuXi AppTecDe】WeChat Official Account
